ライフサイエンスコーパス: transarterial

1 utaneous ablation, and radiation, as well as transarterial and systemic therapies.

2 ion with Yttrium-90 microspheres is a novel, transarterial approach to radiation therapy.

3 Transarterial B/LE is an effective procedure resulting i

4 One of the methods is transarterial bleomycin-lipiodol embolisation (B/LE).

5 The transarterial catheter was then placed in the same coron

6 cute myocardial infarction (AMI) via a novel transarterial catheter.

7 adiotherapy (SBRT), and tumor ablation (with transarterial chemo- or radio-embolization).

8 plete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation

9 plete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation

10 Transarterial-chemo-embolization (TACE) is used for pall

11 Transarterial chemoembolisation (TACE) is standard care

12 Transarterial chemoembolisation (TACE) is standard of ca

13 Transarterial chemoembolisation (TACE) is the standard o

14 r tumour growth and angiogenesis to describe transarterial chemoembolisation (TACE) therapies.

15 atients undergoing surgical resection (16%), transarterial chemoembolization (19%), or radiotherapy (

16 lus ablation (11.1%), ablation alone (7.9%), transarterial chemoembolization (9.5%), and whole-liver

17 Transarterial chemoembolization (cTACE) has been shown t

18 Conventional transarterial chemoembolization (cTACE) is a guideline-a

19 Conventional transarterial chemoembolization (cTACE) is used to treat

20 r carcinoma (HCC) is treated by conventional transarterial chemoembolization (cTACE) using cone-beam

21 d oil to liver tumors following conventional transarterial chemoembolization (cTACE).

22 iocarcinoma (ICC) who underwent conventional transarterial chemoembolization (cTACE).

23 ar patient cohort who underwent conventional transarterial chemoembolization (cTACE).

24 ver tumor viability after drug-eluting beads transarterial chemoembolization (DEB-TACE).

25 RT as bridging therapy, with comparison with transarterial chemoembolization (TACE) and high-intensit

26 lly insufficient future liver remnant (FLR), transarterial chemoembolization (TACE) and portal vein e

27 t patterns including receipt of sorafenib or transarterial chemoembolization (TACE) by HCC-associated

28 outcomes of radiation segmentectomy (RS) and transarterial chemoembolization (TACE) combined with mic

29 Despite transarterial chemoembolization (TACE) for hepatocellula

30 on and/or ablation, and 18 were managed with transarterial chemoembolization (TACE) frequently (n = 1

31 Lipiodol-based transarterial chemoembolization (TACE) has been performe

32 n the detection of residual viable HCC after transarterial chemoembolization (TACE) in a prospective

33 induced by transarterial embolization (TAE)/transarterial chemoembolization (TACE) in a state of cel

34 curate disease monitoring is essential after transarterial chemoembolization (TACE) in hepatocellular

35 TARE was compared with transarterial chemoembolization (TACE) in nine studies o

36 re patient outcomes of HDR brachytherapy and transarterial chemoembolization (TACE) in patients with

37 e to guide the decision for retreatment with transarterial chemoembolization (TACE) in patients with

38 sity focused ultrasound (HIFU) combined with transarterial chemoembolization (TACE) in treating pedia

39 Transarterial chemoembolization (TACE) is an image-guide

40 Transarterial chemoembolization (TACE) is currently reco

41 Transarterial chemoembolization (TACE) is the main treat

42 Background Transarterial chemoembolization (TACE) is the recommende

43 treated by radiofrequency ablation (RFA) +/- transarterial chemoembolization (TACE) or surgical resec

44 rine liver metastases (NELM) after the first transarterial chemoembolization (TACE) procedure.

45 Background Despite transarterial chemoembolization (TACE) serving as the fi

46 Transarterial chemoembolization (TACE) using lipiodol-ba

47 Despite transarterial chemoembolization (TACE) was recommended a

48 Transarterial chemoembolization (TACE) was similarly app

49 Idarubicin-loaded beads for transarterial chemoembolization (TACE) were previously e

50 To evaluate safety and efficacy of combined transarterial chemoembolization (TACE) with doxorubicin-

51 those 15 rabbits, six underwent conventional transarterial chemoembolization (TACE), four underwent c

52 s well as to compare tolerability of SRFA to transarterial chemoembolization (TACE), hepatic resectio

53 ween FAD subtypes and response to sorafenib, transarterial chemoembolization (TACE), immune checkpoin

54 ma (HCC) results in different outcomes after transarterial chemoembolization (TACE).

55 ermediate- and advanced-stage HCC to undergo transarterial chemoembolization (TACE).

56 (MELD) score >10, and absence of neoadjuvant transarterial chemoembolization (TACE).

57 ath with transarterial embolization (TAE) or transarterial chemoembolization (TACE).

58 tumor necrosis after drug-eluting bead (DEB) transarterial chemoembolization (TACE).

59 hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).

60 cellular carcinoma lesions treated with TACE transarterial chemoembolization .

61 s with hepatocellular carcinoma treated with transarterial chemoembolization and includes 377 handcra

62 Minimally invasive therapies such as transarterial chemoembolization and radiofrequency ablat

63 ing tissue diagnosis, and proven efficacy of transarterial chemoembolization and sorafenib as palliat

64 when combining transplant with preoperative transarterial chemoembolization and/or perioperative sys

65 hepatocellular carcinoma who underwent TACE transarterial chemoembolization before surgery.

66 tified patients with a survival benefit from transarterial chemoembolization before therapy.

67 Each patient underwent two sessions of transarterial chemoembolization between February 2013 an

68 paring yttrium-90 microsphere treatment with transarterial chemoembolization by using the Cancer of t

69 yndrome from Lipiodol embolization following transarterial chemoembolization can occur even with smal

70 odol embolization in a patient who underwent transarterial chemoembolization for hepatocellular carci

71 Yttrium-90 achieved higher DS success than transarterial chemoembolization in AC (74% vs. 65%; p <0

72 Yttrium-90 attained higher DS success than transarterial chemoembolization in AC.

73 Transarterial chemoembolization is a widely used therapy

74 Transarterial chemoembolization is accepted therapy for

75 Drug-eluting beads coated with irinotecan transarterial chemoembolization is associated with high

76 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treat

77 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treat

78 e for the routine utilization of CBCT during transarterial chemoembolization of liver cancer.

79 , respectively, as part of the institutional transarterial chemoembolization protocol).

80 d time to progression when used as part of a transarterial chemoembolization regimen for unresectable

81 rc cone-beam CT (during the first and second transarterial chemoembolization sessions, respectively,

82 Background Transarterial chemoembolization with cytotoxic drugs is

83 llular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads

84 l embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-elu

85 To evaluate the safety and efficacy of transarterial chemoembolization with radio-paque doxorub

86 rvival when ICI therapies were combined with transarterial chemoembolization, although data regarding

87 ation, hepatic artery infusion chemotherapy, transarterial chemoembolization, and radioembolization,

88 After progression on chemotherapy, HAIP, transarterial chemoembolization, and transarterial radio

89 fore LT with a multimodal approach combining transarterial chemoembolization, liver resection, radiof

90 hepatic resection, radiofrequency ablation, transarterial chemoembolization, transarterial chemoinfu

91 or hepatocellular carcinoma (HCC), including transarterial chemoembolization, transarterial radioembo

92 benefit of radical therapies, compared with transarterial chemoembolization, was substantial (5-year

93 atocellular carcinoma underwent conventional transarterial chemoembolization.

94 r unresectable disease > 3 cm in diameter is Transarterial Chemoembolization.

95 treated with local interventions, including transarterial chemoembolization.

96 t than those seen after thermal ablation and transarterial chemoembolization.

97 long with imaging findings of ablation after transarterial chemoembolization.

98 He progressed following transarterial chemoemoblisation treatment and was commen

99 y ablation, transarterial chemoembolization, transarterial chemoinfusion, yttrium-90 microsphere radi

100 al mesothelioma were treated with repetitive transarterial chemoperfusion between March 2007 and Marc

101 Transarterial chemoperfusion may have the potential to y

102 Transarterial chemoperfusion was performed by using mito

103 cal resection and vascular reconstruction or transarterial coil embolization.

104 Transarterial coronary ethanol ablation can be effective

105 interventions have been assessed, including transarterial embolisation (with or without chemotherapy

106 Early transarterial embolisation is the most effective interve

107 uate the safety and efficacy of percutaneous transarterial embolization (PTAE) for the treatment of s

108 Bead LUMI) for potential use in image-guided transarterial embolization (TACE) of HCC.

109 Transarterial embolization (TAE) has been extensively us

110 atocellular carcinoma (HCC), the efficacy of transarterial embolization (TAE) has not been widely rec

111 visibility of radiopaque microspheres during transarterial embolization (TAE) in the VX2 rabbit liver

112 Transarterial embolization (TAE) is the gold standard tr

113 Background Transarterial embolization (TAE) is the most common trea

114 Local recurrence after transarterial embolization (TAE) of hepatocellular carci

115 who underwent intra-arterial treatment with transarterial embolization (TAE) or chemoembolization (T

116 treated by inducing ischemic cell death with transarterial embolization (TAE) or transarterial chemoe

117 ay be exploited to potentiate treatment with transarterial embolization (TAE).

118 HCC) cells for surviving ischemia induced by transarterial embolization (TAE)/transarterial chemoembo

119 d advanced interventional procedures such as transarterial embolization and cryoablation are leading

120 c artery ligation (HAL), which recapitulates transarterial embolization in mouse models, to enhance t

121 Conclusion Percutaneous transarterial embolization is effective for the emergenc

122 Transarterial embolization is one therapy clinically use

123 Transarterial embolization of the gastric fundus was per

124 Transarterial embolization of the gastric fundus with fl

125 Transarterial embolization was planned but repeat cerebr

126 These therapies, which include transarterial embolization, intraarterial chemoinfusion,

127 Conclusion Transarterial embolization-induced dynamic alterations o

128 or postembolization syndrome (PES) following transarterial hepatic chemoembolization (TACE) for hepat

129 complications was 10.4% and was highest with transarterial implantation of the Sapien valve (22.3%).

130 data from 463 patients who were treated with transarterial locoregional therapies (chemoembolization

131 r a 9-year period, 285 patients treated with transarterial locoregional therapies underwent scheduled

132 All patients who underwent percutaneous transarterial PDA coil occlusion were studied.

133 ion with 90Y microspheres represents a novel transarterial radiation treatment for liver tumors.

134 of combining US-triggered MB destruction and transarterial radioembolization (TARE) in participants w

135 Transarterial radioembolization (TARE) is a locoregional

136 Transarterial radioembolization (TARE) is a promising al

137 lled studies suggest that yttrium 90 ((90)Y) transarterial radioembolization (TARE) is a safe and eff

138 Transarterial radioembolization (TARE) is an effective t

139 Transarterial radioembolization (TARE) is an image-guide

140 Transarterial radioembolization (TARE) is an increasingl

141 Transarterial radioembolization (TARE) monotherapy was t

142 Background The impact of transarterial radioembolization (TARE) of breast cancer

143 ocellular carcinoma (HCC) lesions undergoing transarterial radioembolization (TARE) therapy and to de

144 e hepatocellular carcinoma (uHCC) with (90)Y transarterial radioembolization (TARE) using pretreatmen

145 The role of transarterial radioembolization (TARE) with yttrium 90 (

146 onclusion Median overall survival (OS) after transarterial radioembolization (TARE) with yttrium 90 m

147 Transarterial radioembolization (TARE) with yttrium-90 m

148 about factors that influence the efficacy of transarterial radioembolization (TARE).

149 ipants with HCC receiving yttrium 90 ((90)Y) transarterial radioembolization (TARE).

150 ocedural SPECT and predict tumor response to transarterial radioembolization (TARE).

151 Transarterial radioembolization achieves high rates of r

152 ndings seen after radiation-based therapies (transarterial radioembolization and stereotactic body ra

153 , HAIP, transarterial chemoembolization, and transarterial radioembolization are valuable treatment o

154 of US-triggered microbubble destruction and transarterial radioembolization is feasible with an exce

155 Conclusion Complete response to transarterial radioembolization was associated with lowe

156 rol in hepatocellular carcinoma treated with transarterial radioembolization with yttrium 90 in the S

157 Transarterial radioembolization with yttrium-90 (Y-90 TA

158 ed transcatheter arterial chemoembolization, transarterial radioembolization, ablation, and radiother

159 , including transarterial chemoembolization, transarterial radioembolization, and thermal ablation.

160 is increasing evidence supporting a role for transarterial radioembolization.

161 some studies showed lower symptom burden for transarterial radiotherapy and radiation therapy.

162 ces, Irving, California) implanted using the transarterial route (25.2% vs. 5.0%, respectively).

163 e therapy (HR, 0.63; 95% CI, 0.52-0.76), and transarterial therapy (HR, 0.83; 95% CI, 0.74-0.92) were

164 transplantation, resection, local ablation, transarterial therapy, or sorafenib) and overall surviva

165 upports the use of chemotherapeutic drugs in transarterial therapy.

166 Approaches were transarterial (transfemoral 73%, transapical 18%, subcla

167 Approaches were either transarterial (transfemoral, 74.6%; subclavian, 5.8%; an